Patients, Biogen Idec hopeful
505811
Lisa Cagle had one burning question she wanted answered at the Multiple Sclerosis Society&#39;s national conference two weeks ago in Denver.
602739
WASHINGTON -- Local biotech powerhouses were comforted by yesterday's congressional testimony that urged federal regulators to take a cautious approach to approving generic versions of biologics, including mandatory human clinical trials.
31543
A group of seven on of the worldâs largest pharmaceutical companies hopes to develop genetic tests to determine which patients would be at risk of drug side effects.
111525
The Food and Drug Administration has approved the first genetics-based lab test to help physicians personalize their patients' drug doses.
89267
Super-cheap genetic scanning is set to jolt medicine, offering patients new insights--and painful choices.
732990
Researchers who found a genetic pattern that predicts who will be helped by a revolutionary new lung cancer drug said on Monday they were looking for patients to help them confirm their findings.
598300
Biogen Idec Inc. and Cardiokine Inc. said they agreed to jointly develop a hyponatremia treatment for patients with congestive heart failure. Lixivaptan is an oral compound being tested for treatment of an imbalance of sodium and water in the body. Lixivaptan is expected to enter a late-stage clinical trial this year. Cambridge-based Biogen will make a $50 million upfront payment ...
214879
DUBLIN -- US drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros ($10.6 billion) for Irish peer Elan , a newspaper reported yesterday.
447422
A new therapy shows glimpses of promise, but proving a benefit in heart patients could be hard.
667096
The biotech's new cancer candidate passes phase 1 trials.
577632
It seemed as if the Food and Drug Administration liked everything about Biogen Idec's new drug for multiple sclerosis.
234249
Moving to strengthen its offerings to treat cancer, Biogen Idec Inc. of Cambridge yesterday signed a deal to license tumor-killing technology from ImmunoGen Inc.
230917
Biogen Idec reported Thursday that its fourth-quarter profit nearly doubled on growing sales of treatments for cancer and multiple sclerosis.
662969
Les donnÃ©es indiquent une augmentation de la rÃ©ponse sÃ©rologique, virologique et biochimique aprÃ¨s 144 semaines de traitement sur des patients naÃ¯fs atteints de l&#39;hÃ©patite B antigÃ¨ne positif.
361386
Introgen Therapeutics Inc., a gene therapy company, on Thursday said its experimental breast cancer treatment showed promise in a mid-stage clinical trial, driving its shares up 24 percent.
494606
A team of researchers from the National Cancer Institute reported yesterday that they have successfully treated two cancer patients using gene therapy, the introduction of genes into the human body for medical purposes.
133355
Biogen Idec Inc. and Elan Corp. said yesterday that they have applied to the Food and Drug Administration for approval to sell Tysabri, a multiple sclerosis drug, to treat patients with Crohn's disease.